Cargando…

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

SIMPLE SUMMARY: Approximately 7–50% of patients with non-small-cell lung cancer (NSCLC) develop oligometastases, which are new tumors found in another part of the body, arising from cancer cells of the original tumor that have travelled through the body. In recent years, these patients have been inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Hsing, Ho, Ue-Cheung, Kuo, Lu-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909159/
https://www.ncbi.nlm.nih.gov/pubmed/35267658
http://dx.doi.org/10.3390/cancers14051350
_version_ 1784666058967220224
author Chen, Yi-Hsing
Ho, Ue-Cheung
Kuo, Lu-Ting
author_facet Chen, Yi-Hsing
Ho, Ue-Cheung
Kuo, Lu-Ting
author_sort Chen, Yi-Hsing
collection PubMed
description SIMPLE SUMMARY: Approximately 7–50% of patients with non-small-cell lung cancer (NSCLC) develop oligometastases, which are new tumors found in another part of the body, arising from cancer cells of the original tumor that have travelled through the body. In recent years, these patients have been increasingly regarded as a distinct group that could benefit from treatment that intends to cure the disease, rather than palliative care, to achieve a better clinical outcome. Various treatment procedures have been developed for treating NSCLC patients with different oligometastatic sites. In addition, the newly proposed uniform definition for oligometastases as well as ongoing trials may lead to increased appropriate patient selection and evaluation of treatment effectiveness. The aim of this review article is to summarize the latest evidence regarding optimal management strategies for NSCLC patients with oligometastases. ABSTRACT: Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct entity that is different from localized and disseminated diseases. The definition of oligometastatic NSCLC varies across studies in past decades owing to the use of different imaging modalities; however, a uniform definition of oligometastatic NSCLC has been proposed, and this may facilitate trial design and evaluation of certain interventions. Patients with oligometastatic NSCLC are candidates for curative-intent management, in which local ablative treatment, such as surgery or stereotactic radiosurgery, should be instituted to improve clinical outcomes. Although current guidelines recommend that local therapy for thoracic and metastatic lesions should be considered for patients with oligometastatic NSCLC with stable disease after systemic therapy, optimal management strategies for different oligometastatic sites have not been established. Additionally, the development of personalized therapies for individual patients with oligometastatic NSCLC to improve their quality of life and overall survival should also be addressed. Here, we review relevant articles on the management of patients with oligometastatic NSCLC and categorize the disease according to the site of metastases. Ongoing trials are also summarized to determine future directions and expectations for new treatment modalities to improve patient management.
format Online
Article
Text
id pubmed-8909159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89091592022-03-11 Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update Chen, Yi-Hsing Ho, Ue-Cheung Kuo, Lu-Ting Cancers (Basel) Review SIMPLE SUMMARY: Approximately 7–50% of patients with non-small-cell lung cancer (NSCLC) develop oligometastases, which are new tumors found in another part of the body, arising from cancer cells of the original tumor that have travelled through the body. In recent years, these patients have been increasingly regarded as a distinct group that could benefit from treatment that intends to cure the disease, rather than palliative care, to achieve a better clinical outcome. Various treatment procedures have been developed for treating NSCLC patients with different oligometastatic sites. In addition, the newly proposed uniform definition for oligometastases as well as ongoing trials may lead to increased appropriate patient selection and evaluation of treatment effectiveness. The aim of this review article is to summarize the latest evidence regarding optimal management strategies for NSCLC patients with oligometastases. ABSTRACT: Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct entity that is different from localized and disseminated diseases. The definition of oligometastatic NSCLC varies across studies in past decades owing to the use of different imaging modalities; however, a uniform definition of oligometastatic NSCLC has been proposed, and this may facilitate trial design and evaluation of certain interventions. Patients with oligometastatic NSCLC are candidates for curative-intent management, in which local ablative treatment, such as surgery or stereotactic radiosurgery, should be instituted to improve clinical outcomes. Although current guidelines recommend that local therapy for thoracic and metastatic lesions should be considered for patients with oligometastatic NSCLC with stable disease after systemic therapy, optimal management strategies for different oligometastatic sites have not been established. Additionally, the development of personalized therapies for individual patients with oligometastatic NSCLC to improve their quality of life and overall survival should also be addressed. Here, we review relevant articles on the management of patients with oligometastatic NSCLC and categorize the disease according to the site of metastases. Ongoing trials are also summarized to determine future directions and expectations for new treatment modalities to improve patient management. MDPI 2022-03-06 /pmc/articles/PMC8909159/ /pubmed/35267658 http://dx.doi.org/10.3390/cancers14051350 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Yi-Hsing
Ho, Ue-Cheung
Kuo, Lu-Ting
Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title_full Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title_fullStr Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title_full_unstemmed Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title_short Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
title_sort oligometastatic disease in non-small-cell lung cancer: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909159/
https://www.ncbi.nlm.nih.gov/pubmed/35267658
http://dx.doi.org/10.3390/cancers14051350
work_keys_str_mv AT chenyihsing oligometastaticdiseaseinnonsmallcelllungcanceranupdate
AT houecheung oligometastaticdiseaseinnonsmallcelllungcanceranupdate
AT kuoluting oligometastaticdiseaseinnonsmallcelllungcanceranupdate